U.S. Stocks in Motion | Zai Lab (ZLAB.US) Rises Over 2% on Positive Phase Ib Data for Investigational ADC Zoci

Zhitong Finance APP has learned that on Friday, Zai Lab (ZLAB.US) rose nearly 10% in early trading, and as of press time, was up more than 2% at $22.62. On the news front, on October 23, Zai Lab announced data from the global Phase Ib clinical study of its investigational antibody-drug conjugate (ADC) Zocilurtatug Pelitecan (abbreviated as "Zoci," formerly code-named ZL-1310) for first-line extensive-stage small cell lung cancer. The relevant results will be presented on October 26 at the 2026 European Society for Medical Oncology (ESMO) Congress.